Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

S100P (S100 calcium binding protein P)

Written2008-07Sayka Barry, Tatjana Crnogorac-Jurcevic
Institute of Cancer, Barts, The London, Queen Mary's School of Medicine, Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom

(Note : for Links provided by Atlas : click)


Alias (NCBI)MIG9
HGNC (Hugo) S100P
HGNC Previous nameS100 calcium-binding protein P
LocusID (NCBI) 6286
Atlas_Id 42196
Location 4p16.1  [Link to chromosome band 4p16]
Location_base_pair Starts at 6693878 and ends at 6697170 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping S100P.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
KIAA0232 (4p16.1)::S100P (4p16.1)S100P (4p16.1)::CHD1 (5q15)


Description S100P gene contains two exons and one intron. Genomic size of 3,332 bases.
Transcription 1279 bases mRNA; 288 bases coding sequences. The transcript is on Chromosome 4 at location 6,745,697-6,749,797.
Pseudogene None identified.


Description S100P protein consists of 95 amino acids with a molecular weight of 10.4 kDa.
S100P is a Ca2+ binding protein that belongs to S100 family ("Soluble in 100% saturated solution with ammonium sulfate") which was first isolated from human placenta and is therefore designated as "P". S100 family includes at least 26 members, which are thought to be expressed only in vertebrates and are present in a tissue and cell-specific manner. S100 proteins are characterized by common structural motifs including 2 EF-hands (helix-loop-helix calcium binding domains) with different affinities for calcium ions, a central hinge region and the C-terminal extension. The N-terminal half of the protein contains an unconventional EF hand that binds calcium with lower affinity, while the C-terminal is canonical and binds calcium with high affinity. The connecting hinge region and the C-terminal extension are the most variable regions and thus determine the functional specificity of S100 family members, including S100P. In addition to Ca2+, S100P also binds Zn2+ and Mg2+ and can form homo- and heterodimers.
Expression S100P is expressed in various normal tissues including placenta, lung, heart, kidney, bladder, skeletal muscle, bone marrow, spleen, mammary epithelium, epidermis, prostate gland, gastric and intestinal mucosa, and malignant tissues such as pancreatic ductal adenocarcinoma, pancreatic intraductal papillary mucinous neoplasm, non-small-cell lung cancer, melanoma, gastric adenocarcinoma, ovarian, breast, colon and prostate carcinoma as well as in the body fluids such as tear, pancreatic juice, blood and urine.
Localisation Cytoplasm, nucleus, also secreted in the culture media.
Function S100P is involved in diverse biological functions but the exact role or mechanism of its action is still largely unknown. Upon binding of calcium ions S100P undergoes a conformational change that results in an exposure of a hydrophobic surface which allows the interaction with specific target proteins. To date, several S100P interacting partners have been identified including S100P binding protein S100PBP, EZR, S100A1, ECD, CacyBP, RAGE, S100Z and S100A6, but the consequences of their interactions are not fully understood.
Homology S100P shares 50% sequence identity with human S100A1 and 44% identity with S100B.


Note Mutations have not been reported.

Implicated in

Entity Cancers
Disease S100P has been associated with the progression of several types of cancer including pancreatic, prostate, non-small cell lung, breast, and colorectal cancer.
Oncogenesis S100P has been implicated in migration, invasion, proliferation and survival of cancer cells in vitro and increased tumour growth in vivo. In fibroblasts, S100P has been shown to function as an autocrine growth and survival factor that enhanced cell proliferation and survival by activating RAGE receptor through MAPK and NF-kB signaling.
Entity Pancreatic cancer
Oncogenesis The up-regulation of S100P is an early event in the development of pancreatic cancer and its expression increases throughout the progression of pancreatic intraepithelial neoplasia (PanINs) to invasive pancreatic ductal adenocarcinoma. S100P plays a critical role in the maintenance of the structural organization of intermediate filaments (cytokeratins 8, 18 and 19) and actin cytoskeleton, and its over-expression changes the phosphorylation status of the actin regulatory protein cofilin. Over-expression of S100P also increases the expression of S100A6 and cathepsin D, both of which are involved in cellular invasion. As S100P is expressed early in pancreatic ductal adenocarcinoma and is secreted into body fluids, it can serve as an useful diagnostic marker.
Entity Prostate cancer
Oncogenesis In prostate cancer over-expression of S100P increases cell growth both in vitro and in vivo. S100P over-expression also up-regulates androgen receptor that leads to prostate cancer progression. Its expression has also been associated with poor clinical prognosis of patients with this malignancy.
Entity Non-small-cell lung cancer
Oncogenesis Higher levels of S100P have been correlated with progression to metastasis and decreased survival in patients with lung cancer. This may also serve as a predictor of distant metastasis and poor survival in non-small cell lung carcinomas.
Entity Colorectal cancer
Oncogenesis In colon cancer, expression of S100P correlates with resistance to chemotherapy and has also been associated with doxorubicin resistance in colon cancer cell lines.
Entity Breast cancer
Oncogenesis S100P has been associated with immortalization of breast cancer cells in vitro and tumour progression in vivo. Higher level of S100P expression has also been correlated with decreased survival in patients with breast cancer.
Entity Other cancer types
Note S100P is also expressed at higher levels in gastric, ovarian and cervical carcinomas.


The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins.
Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M.
Genome Biol. 2006;7(9):R80.
PMID 16948836
S100P promotes pancreatic cancer growth, survival, and invasion.
Arumugam T, Simeone DM, Van Golen K, Logsdon CD.
Clin Cancer Res. 2005 Aug 1;11(15):5356-64.
PMID 16061848
Functional evidence implicating S100P in prostate cancer progression.
Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S.
Int J Cancer. 2008 Jul 15;123(2):330-9.
PMID 18452169
S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties.
Becker T, Gerke V, Kube E, Weber K.
Eur J Biochem. 1992 Jul 15 ;207(2): 541-7.
PMID 1633809
Gene-expression profiles predict survival of patients with lung adenocarcinoma.
Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S.
Nat Med. 2002 Aug; 8(8): 816-24.
PMID 12118244
Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression.
Bertram J, Palfner K, Hiddemann W, Kneba M.
Anticancer Drugs. 1998 Apr ;9(4): 311-7.
PMID 9635921
Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.
Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP, Lemoine NR.
J Pathol. 2003 Sep;201(1):63-74.
PMID 12950018
S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer.
Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zänker KS, Metzger R, Schneider PM, Gerke V, Thomas M, Berdel WE, Serve H, Müller-Tidow C.
Cancer Res. 2004 Aug 15;64(16):5564-9.
PMID 15313892
Intracellular and extracellular roles of S100 proteins.
Donato R.
Microsc Res Tech. 2003 Apr 15;60(6):540-51
PMID 12645002
Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.
Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, Brentnall TA, Lüttges J, Klöppel G, Lemoine NR.
Am J Pathol. 2005 Jan;166(1):81-92.
PMID 15632002
CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family.
Filipek A, Jastrzebska B, Nowotny M, Kuznicki J.
J Biol Chem. 2002 Aug 9; 277(32): 28848-52.
PMID 12042313
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.
Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, Huang EH.
Dis Colon Rectum. 2007 Aug;50(8):1230-40.
PMID 17587138
S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo.
Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X, Russo J.
Int J Oncol. 2000 Feb; 16(2): 231-40.
PMID 10639564
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.
Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH.
Am J Pathol. 2002 Apr;160(4):1239-49.
PMID 11943709
Characterization of the tissue-specific expression of the s100P gene which encodes an EF-hand Ca2+-binding protein.
Jin G, Wang S, Hu X, Jing Z, Chen J, Ying K, Xie Y, Mao Y.
Mol Biol Rep. 2003 Dec;30(4):243-8.
PMID 14672411
Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P.
Koltzscher M, Neumann C, König S, Gerke V.
Mol Biol Cell. 2003 Jun;14(6):2372-84.
PMID 12808036
Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis.
Lin F, Shi J, Liu H, Hull ME, Dupree W, Prichard JW, Brown RE, Zhang J, Wang HL, Schuerch C.
Am J Surg Pathol. 2008 Jan;32(1):78-91.
PMID 18162774
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.
Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S.
Cancer Res. 2003 May 15;63(10):2649-57.
PMID 12750293
Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.
Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, Kallioniemi OP.
Cancer Res. 2002 Mar 1;62(5):1256-60.
PMID 11888886
Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection.
Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, Katagiri T.
Oncogene. 2004 Mar 25;23(13):2385-400.
PMID 14767473
Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins.
Nowotny M, Spiechowicz M, Jastrzebska B, Filipek A, Kitagawa K, Kuznicki J.
J Biol Chem. 2003 Jul 18;278(29):26923-8.
PMID 12746458
S100P is an early developmental marker of pancreatic carcinogenesis.
Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M.
Clin Cancer Res. 2006 Sep 15;12(18):5411-6.
PMID 17000674
The calcium-binding protein S100P in normal and malignant human tissues.
Parkkila S, Pan PW, Ward A, Gibadulinova A, Oveckova I, Pastorekova S, Pastorek J, Martinez AR, Helin HO, Isola J.
BMC Clin Pathol. 2008 Feb 18;8:2.
PMID 18282279
Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.
Sato N, Fukushima N, Matsubayashi H, Goggins M.
Oncogene. 2004 Feb 26;23(8):1531-8.
PMID 14716296
Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.
Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS.
Cancer Res. 2006 Jan 15;66(2):1199-207.
PMID 16424059
The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.
Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, Crnogorac-Jurcevic T.
Cancer Res. 2007 Sep 15;67(18):8633-42.
PMID 17875703
The crystal structure at 2A resolution of the Ca2+ -binding protein S100P.
Zhang H, Wang G, Ding Y, Wang Z, Barraclough R, Rudland PS, Fernig DG, Rao Z.
J Mol Biol. 2003 Jan 24;325(4):785-94.
PMID 12507480
Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors.
de Souza GA, Godoy LM, Mann M.
Genome Biol. 2006;7(8):R72.
PMID 16901338


This paper should be referenced as such :
Barry, S ; Crnogorac-Jurcevic, T
S100P (S100 calcium binding protein P)
Atlas Genet Cytogenet Oncol Haematol. 2009;13(6):429-431.
Free journal version : [ pdf ]   [ DOI ]

Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
  i(4p) in myeloid malignancies

External links


HGNC (Hugo)S100P   10504
Entrez_Gene (NCBI)S100P    S100 calcium binding protein P
GeneCards (Weizmann)S100P
Ensembl hg19 (Hinxton)ENSG00000163993 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000163993 [Gene_View]  ENSG00000163993 [Sequence]  chr4:6693878-6697170 [Contig_View]  S100P [Vega]
ICGC DataPortalENSG00000163993
TCGA cBioPortalS100P
AceView (NCBI)S100P
Genatlas (Paris)S100P
SOURCE (Princeton)S100P
Genetics Home Reference (NIH)S100P
Genomic and cartography
GoldenPath hg38 (UCSC)S100P  -     chr4:6693878-6697170 +  4p16.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)S100P  -     4p16.1   [Description]    (hg19-Feb_2009)
GoldenPathS100P - 4p16.1 [CytoView hg19]  S100P - 4p16.1 [CytoView hg38]
Genome Data Viewer NCBIS100P [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AF539739 AI202505 AY423724 BC006819 BI259919
RefSeq transcript (Entrez)NM_005980
Consensus coding sequences : CCDS (NCBI)S100P
Gene ExpressionS100P [ NCBI-GEO ]   S100P [ EBI - ARRAY_EXPRESS ]   S100P [ SEEK ]   S100P [ MEM ]
Gene Expression Viewer (FireBrowse)S100P [ Firebrowse - Broad ]
GenevisibleExpression of S100P in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)6286
GTEX Portal (Tissue expression)S100P
Human Protein AtlasENSG00000163993-S100P [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP25815   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP25815  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP25815
Domaine pattern : Prosite (Expaxy)EF_HAND_2 (PS50222)    S100_CABP (PS00303)   
Domains : Interpro (EBI)EF-hand-dom_pair    EF_hand_dom    S-100_dom    S100/CaBP-9k_CS    S100_Ca-bd_sub   
Domain families : Pfam (Sanger)S_100 (PF01023)   
Domain families : Pfam (NCBI)pfam01023   
Domain families : Smart (EMBL)EFh (SM00054)  S_100 (SM01394)  
Conserved Domain (NCBI)S100P
PDB (RSDB)1J55    1OZO    2MJW   
PDB Europe1J55    1OZO    2MJW   
PDB (PDBSum)1J55    1OZO    2MJW   
PDB (IMB)1J55    1OZO    2MJW   
Structural Biology KnowledgeBase1J55    1OZO    2MJW   
SCOP (Structural Classification of Proteins)1J55    1OZO    2MJW   
CATH (Classification of proteins structures)1J55    1OZO    2MJW   
AlphaFold pdb e-kbP25815   
Human Protein Atlas [tissue]ENSG00000163993-S100P [tissue]
Protein Interaction databases
IntAct (EBI)P25815
Ontologies - Pathways
Ontology : AmiGOmagnesium ion binding  calcium ion binding  protein binding  extracellular region  nucleus  nucleoplasm  cytoplasm  cytoplasm  cytoplasm  response to organic substance  microvillus membrane  secretory granule lumen  protein homodimerization activity  neutrophil degranulation  endothelial cell migration  endothelial cell migration  cadherin binding  transition metal ion binding  calcium-dependent protein binding  calcium-dependent protein binding  extracellular exosome  
Ontology : EGO-EBImagnesium ion binding  calcium ion binding  protein binding  extracellular region  nucleus  nucleoplasm  cytoplasm  cytoplasm  cytoplasm  response to organic substance  microvillus membrane  secretory granule lumen  protein homodimerization activity  neutrophil degranulation  endothelial cell migration  endothelial cell migration  cadherin binding  transition metal ion binding  calcium-dependent protein binding  calcium-dependent protein binding  extracellular exosome  
REACTOMEP25815 [protein]
REACTOME PathwaysR-HSA-6798695 [pathway]   
NDEx NetworkS100P
Atlas of Cancer Signalling NetworkS100P
Wikipedia pathwaysS100P
Orthology - Evolution
GeneTree (enSembl)ENSG00000163993
Phylogenetic Trees/Animal Genes : TreeFamS100P
Homologs : HomoloGeneS100P
Homology/Alignments : Family Browser (UCSC)S100P
Gene fusions - Rearrangements
Fusion : MitelmanS100P::CHD1 [4p16.1/5q15]  
Fusion : QuiverS100P
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerS100P [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)S100P
Exome Variant ServerS100P
GNOMAD BrowserENSG00000163993
Varsome BrowserS100P
ACMGS100P variants
Genomic Variants (DGV)S100P [DGVbeta]
DECIPHERS100P [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisS100P 
ICGC Data PortalS100P 
TCGA Data PortalS100P 
Broad Tumor PortalS100P
OASIS PortalS100P [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICS100P  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DS100P
Mutations and Diseases : HGMDS100P
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)S100P
DoCM (Curated mutations)S100P
CIViC (Clinical Interpretations of Variants in Cancer)S100P
NCG (London)S100P
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry S100P
NextProtP25815 [Medical]
Target ValidationS100P
Huge Navigator S100P [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDS100P
Pharm GKB GenePA34913
Clinical trialS100P
canSAR (ICR)S100P
DataMed IndexS100P
PubMed131 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:27:31 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us